Core Viewpoint - The company anticipates a net profit loss of 250 million to 300 million yuan for the fiscal year 2025, compared to a net profit of 26.57 million yuan in the same period last year [1] Group 1: Company Performance - The company's chain pharmacy segment is experiencing a temporary decline in performance due to changes in the macro market environment and increased competition [1] - The actual operating performance of the subsidiaries acquired earlier did not meet expectations due to industry conditions, operational issues, and business integration challenges [1] Group 2: Financial Impact - The company conducted impairment testing on goodwill related to the acquisitions based on prudent financial assessment principles, leading to significant asset impairment losses for the current period [1] - The substantial impairment losses have a notable impact on the current profit [1]
达嘉维康：预计2025年净利润亏损2.5亿元-3亿元